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Abstract
Background: Hypertension is a risk factor for cardiovascular disease, and the prevalence of hypertension tends to
increase with age. Current treatments for hypertension have side effects and poor adherence. Qigong has been
studied as an alternative therapy for hypertension; however, the types of qigong used in those studies were
diverse, and there have not been many well-designed randomized controlled trials.
Our objectives are the following: 1) To evaluate the effects of qigong on blood pressure, health status and
hormone levels for pre- or mild hypertension. 2) To test the methodological appropriateness of this clinical trial
and calculate a sample size for future randomized trials.
Methods: Forty subjects with pre- or mild hypertension will be randomized to either the qigong exercise group or
the non-treated group. Participants in the qigong group will conduct qigong exercises 5 times per week for 8
weeks, and participants in the non-treated group will maintain their current lifestyle, including diet and exercise.
The use of antihypertensive medication is not permitted. The primary endpoint is a change in patient blood
pressure. Secondary endpoints are patient health status (as measured by the SF-36 and the MYMOP2
questionnaires) and changes in hormone levels, including norepinephrine, epinephrine, and cortisol.
Discussion: This study will be the first randomized trial to investigate the effectiveness of qigong exercises for the
treatment of pre- and mild hypertension. The results of this study will help to establish the optimal approach for
the care of adults with pre- or mild hypertension.
Trial registration: Clinical Research Information Service KCT0000140
Background
Hypertension is a risk factor for future cardiovascular
events, including heart attack, heart failure, and stroke,
which are the most frequent causes of death in devel-
oped countries [1,2]. Hypertension affects approximately
one billion individuals worldwide, and the prevalence of
hypertension tends to increase with age [3]. In Korea,
hypertension affects more than 30% of people over the
age of 30 and up to 65% of people over 65 [4].
Current interventions for hypertension include sodium
restriction, pharmacological management, and lifestyle
modifications, such as stress management and exercise.
However, in clinical practice, hypertension can be diffi-
cult to control, due to poor adherence to prescribed
interventions [5]. Lifestyle interventions are difficult to
achieve and maintain, and antihypertensive medications
present risks of side effects.
Qigong is a common healing technique in Oriental
medicine and has been used clinically for preventing
and curing disease, as well as for improving and main-
taining overall health [6]. It has been claimed that
qigong can foster health and healing by promoting the
smooth flow of qi throughout the body so that the body
can heal itself [7]. Qigong includes two concepts: qi, the
vital energy of the body, and gong, the training or culti-
vation of qi. Medical qigong is divided into internal and
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cises, including breathing, meditation, focus of intention
and rhythmical movements, while external qigong is
performed by a trained practitioner in order to deliver
qi energy to the patient [8]. It is generally accepted that
internal qigong is the more beneficial aspect for the pro-
motion of good health [9].
Qigong has been found to have effects on various con-
ditions, such as cancer [10-12], pain [13] and diabetes
[14]. Qigong has also been studied as an alternative
therapy for controlling blood pressure. Previous such
research has concluded that patients with essential
hypertension practicing qigong for less than 1 year had
improved blood pressure (BP) control compared with
non-treated controls [7].
However, well-designed rigorous randomized con-
trolled trials (RCTs) related to the effects of qigong on
BP control are still scarce [15]. Although most qigong
trials have targeted essential hypertension, the stages of
hypertension exhibited by study subjects were diverse,
and some studies did not describe each patient’se x a c t
blood pressure. In addition, there has been no trial
assessing the effects of qigong on pre-hypertension. To
assess the effects of qigong for pre- and mild hyperten-
sion through a high-quality RCT, a pilot study to evalu-
ate qigong should be conducted.
The aims of this pilot study are the following: (1) to
evaluate the effects of internal qigong on blood pressure,
health status and hormone levels in patients with pre-
or mild hypertension and (2) to test the methods and
calculate a sample size for future randomized trials to
investigate further the clinical value of qigong in con-
trolling hypertension.
Methods/Design
Study design
The study is a 2-parallel group, randomized controlled
trial to compare qigong with no treatment for pre- and
mild hypertension on the following outcomes: blood
pressure, Health Related Quality of Life (HRQOL), clini-
cal symptoms and hormone levels. The study design is
depicted in Figure 1.
Ethics
The protocol has been approved by the institutional
review boards of Dongeui University, where the study
will take place. This study has been registered with the
‘Clinical Research Information Service’, Republic of
Korea, which is a registry in the WHO Registry Network
[16].
This study will be monitored by an independent data
and safety monitoring board. Advertisements for volun-
tary subjects will be printed in local newspapers and
posted on notice boards in the local community. All of
the participants will provide written informed consent.
Participants
Inclusion criteria
The inclusion criteria are as follows: (1) patient age
between 19 and 65 years, (2) systolic blood pressure
between 120 and 159 mm Hg and/or diastolic blood
pressure (DBP) between 80 and 99 mm Hg as measured
in a sitting position, and (3) the absence of objective
signs of hypertension end-stage disease.
Exclusion criteria
The exclusion criteria are as follows: (1) serious sympto-
matic cardiac disease, including previous myocardial
infarction, angina or heart failure; (2) previous transient
ischemic attacks or stroke; (3) secondary hypertension;
(4) taking medications that could affect hypertension,
such as stimulants, central nervous system depressants;
(5) necessity of antihypertensive medications; (6) conco-
mitant illness that precludes participation, including dia-
betes, cancer, infectious disease, renal failure; (7)
pregnancy or the possibility of pregnancy; (8) moderate
to high risk of cardiac complications during exercise; or
(9) inability to comprehend and complete the study
assessments or comply with the study instructions
(Table 1).
Figure 1 Flowchart of the study design.
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We will recruit 40 participants; all participants will pro-
vide written consent before participation in the study.
The clinical research coordinator (CRC) will initially
screen by telephone each potential participant against
the inclusion and exclusion criteria. Willing potential
participants will be given an appointment at the center
for the qigong trial. A screening log will be maintained
to record the inclusion/exclusion criteria for all those
participants. The CRC will briefly explain the purpose of
the study and ask if they have an interest in participat-
ing. The CRC will also record basic demographic and
medical information.
Sample size
There are no previous clinical trials to evaluate the
effect of qigong on pre- or mild hypertension. There-
fore, this study is designed as a pilot study to calculate
the appropriate sample size for future randomized clini-
cal trials. Each group will include 20 participants, which
is the minimum sample size for evaluating the effect of
qigong [17,18].
Randomization and allocation concealment
The subjects admitted to the trial will be randomized to
either the qigong group or the non-treated group. Parti-
cipants will be randomized before the first treatment by
an online centralized randomization service. Randomiza-
tion will be stratified by age and sex.
Allocation concealment will be ensured, as the service
will not release the randomization code until the
patients are recruited into the trial after all baseline
measurements are completed.
Collection of demographic and lifestyle information
Each patient’s medical history, including current medi-
cation, surgical history, and the presence of other dis-
eases, will be recorded at baseline. Lifestyle factors,
including diet, exercise, smoking, and drinking alcohol,
will also be documented. To investigate other risk fac-
tors for hypertension, height,w e i g h t ,w a i s ta n dh i pc i r -
cumference, and other demographic information will
also be measured. Body-fat percentage will be estimated
by measuring bioelectrical impedance. A questionnaire
for syndrome differentiation will be used based on gen-
eral condition, sweating, pain, sleeping, breathing, skin
and pulse.
Blinding
Outcome assessors will be blind to group allocation and
will not be involved in providing intervention. However,
it will be difficult to blind the participants because the
control group will not receive any intervention.
Intervention
Qigong exercise
Although there have been several qigong trials for
hypertension, the type of qigong used in those trials was
diverse, and there has been no standardized qigong
exercises for the treatment of hypertension. We have
developed a qigong protocol for the treatment of hyper-
tension based on discussions with three qigong
professionals.
Qigong will be taught by an instructor with expertise
in qigong. The participants will visit the clinic and
take 3 qigong classes per week for 8 weeks. Each
qigong class lasts 30 minutes, including a warm-up (5
min) and a cool-down (5 min) portion. In addition, the
subjects will be asked to practice qigong at home for
30 min more than 2 times a week for the duration of
the study. The purpose of qigong exercise is to
improve kidney and liver function, to improve blood
circulation and to lower blood pressure through calm-
ing (Table 2).
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
19-65 years of age Serious symptomatic cardiac disease, including previous myocardial infarction, angina or heart
failure
Pre- or Stage 1 hypertension
-Systolic blood pressure between 120 and 159
mm Hg
- Diastolic blood pressure between 80 and 99
mm Hg
Previous transient ischemic attacks or stroke
No objective signs of hypertension end-stage
disease
Secondary hypertension
Taking medications that could affect hypertension
Necessity to continue antihypertensive medications
Concomitant illness that precludes participation, including diabetes, cancer, infectious disease,
renal failure
Pregnancy or chance of pregnancy
Moderate to high risk for cardiac complications during exercise
Inability to comprehend and complete study assessments or comply with study instructions
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terms of the number of qigong classes attended and the
number of home repetitions per week. No antihyperten-
sive medications or medications that affect blood pres-
sure will be permitted during the study.
Non-treated group
The control group will receive no instruction in qigong
exercise. They will be asked to maintain their routine
lifestyle, including diet, exercise, work and other
activities.
Outcome measures
Primary
The primary outcome will be changes in patient blood
pressure before and after qigong exercises. Blood pres-
sure will be taken at every visit. The subjects will be
fitted with a BP cuff on the right arm and allowed to sit
quietly for 5 minutes. A trained research nurse will
measure the blood pressure carefully with the subject in
the seated position 3 times after resting for at least 10
min in a temperature-controlled room. Three measure-
ments will be carried out at 5-min intervals. The mean
of these 3 measurements will be used in the data
analysis.
Subjects will be instructed to wear loose and comfor-
table clothing. The investigators will refrain from wear-
ing laboratory coats during all sessions, as the use of
such apparel has been associated with increased BP in
some patients (white-coat hypertension).
Secondary
Subjects will be asked to complete two questionnaires,
specifically, the MOS Short Form 36-item (SF-36) (Kor-
ean version) and the Measure Yourself Medical Out-
come Profile (MYMOP2). These surveys were selected
based on the aims of the trial and on their clinical rele-
vance and feasibility. The SF-36 is a widely used, reli-
able, valid and responsive measure of outcome health
survey. The SF-36 consists of eight scales: physical func-
tion, role-physical, bodily pain, general health, mental
health, role-emotional, social function, and vitality.
The MYMOP is a patient-generated outcome ques-
tionnaire, which is problem-specific but includes general
well-being. MYMOP aims to measure the outcomes that
the patient considers to be most important. MYMOP is
Table 2 Composition of Qigong
Stage Stage Motions
Warm-up 1 Meditate for 1 minute, swing your arms and shoulders and flex your waist, knees and ankles.
1
st 1 Lift both hands overhead, locking your fingers together while bending and extending your knees.
2 Lean your body to the right while breathing in, and stand straight, while breathing out. Repeat 4 times to the left and right,
alternating.
2
nd 1 Advance your left foot, and lower your right hand from the left of your head to your right leg drawing an oblique line quickly.
Repeat this 8 times to the left and right, alternating.
3
rd 1 Advance your right foot, lift your right arm and support your right elbow with the back of your left hand.
2 Lower your body quickly while bending your knees and clenching your right fist. Repeat this 8 times to the left and right,
alternating.
4
th 1 Advance your left foot and put your left hand on your left knee. Put your right hand on your left hand and push down as much
as possible. Lift up right hand to the right. Repeat this 8 times to the left and right, alternating.
5
th 1 Put your feet apart and relax your wrists and lift your hands slowly forward.
2 Lower your hands while bending your knees. Repeat this 10 times.
6
th 1 Support your back with your hands and lean back.
2 Bend your waist forward and sweep the back of your legs with your hands.
3 With straight waist, lift your hands overhead while breathing in and lower them, while breathing out. Repeat this 8 times.
7
th 1 Put your feet apart and twist your body backward to the left.
2 Reverse your palms and gather them on your forehead.
3 Look straight ahead slowly again. Repeat this 8 times to the left and right, alternating.
8
th 1 Lift your arms to the right.
2 Lower your body while crossing your left leg backward, and stand straight. Repeat this 10 times to the left and right, alternating
9
th 1 Bend your knees and lift your arms in parallel and make a circle.
2 Extend your knees and spread your arms. Twist your upper body backward to the right.
3 Stand straight while breathing out. Repeat this 8 times to the left and right, alternating.
10
th 1 With your left foot advanced, lift your right arm up. Tap the area of your liver with your left hand 14 times. Repeat this
movement 2 times.
Cool-
down
1 Bend your knees and lift up your arms shoulder high. Put your feet apart while breathing in, and gather your feet while
breathing out. Repeat this movement 10 times to the left and right, alternating.
2 Concentrate your mind on an acupoint KI1 on the bottom of your foot for 1 minute.
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these symptoms can be physical, emotional or social
[19].
Heart rate will be assessed on every visit, and ques-
tionnaires will be administered at weeks 0, 4 and 8.
Changes in norepinephrine, cortisol, renin, angiotensin,
total cholesterol, and triglycerides will be examined
through blood tests at weeks 0 and 8. Blood samples
will be taken in the morning after an overnight fast to
achieve standard conditions with respect to dietary
intake.
Follow-up
Four weeks after completion of the 8 weeks of qigong
exercise, blood pressure, heart rate, and the SF-36 and
MYMOP2 questionnaires will be evaluated. The follow-
up assessment is designed to evaluate the long-term
effect of qigong exercise.
Data analysis
Collected data will be recorded on standardized forms.
Descriptive statistics will be calculated for dependent
and independent variables. This analysis will include
summary statistics of demographic information and out-
come measures.
T h ep r i m a r ya n a l y s i so ft h ed a t aw i l lb eu n d e r t a k e n
using the principle of intent-to-treat (ITT). Our ITT
analysis will include all participants, including those
who are not fully compliant and those missing out-
come data. We will evaluate the effectiveness of
qigong exercise and no treatment on blood pressure
at 8 weeks using an analysis of covariance
(ANCOVA).
Demographic and clinical characteristics of subjects
in the qigong and the non-treated group will be com-
pared upon admission using a 2-sample t-test (contin-
uous data) and chi-square analysis (normal data).
Nonparametric methods will be used when assump-
tions of normality are violated. To control for baseline
differences between groups, variables that are signifi-
cantly different at baseline will serve as covariates in
the analyses. Data will be analyzed on an intention-to-
treat basis. Software will include the Access and SAS
version 9.1 programs. The alpha level will be set at <
0.05.
Adverse events will be reported to the data and safety
monitoring board. Adverse events will be recorded
when participants present with complaints at any time
and will be based on the questioning of participants.
Serious adverse events will be recorded as required by
the International Conference on Harmonization Guide-
line E2A. We will submit the results of the trial for pub-
lication in an appropriate journal irrespective of
outcome. We will report the trial in accordance with
the CONSORT statements.
Discussion
The primary end point for this study is the change in
patient blood pressure from baseline to 8 weeks post-
therapy. Eight-week changes in hormone levels and
health status, as measured by SF-36 and MYMOP2, are
secondary end points. The primary comparison is
between participants randomly assigned to qigong exer-
cises versus no intervention. Subgroup analyses for age,
gender and baseline BP will be conducted by including
each classification.
Many qigong researchers consider that the qigong
effects on the human body are systemic without target-
ing one particular element, such as BP [7]. Therefore,
we will use the MYMOP 2 and the SF-36 question-
naires, which can measure the quality of life, health sta-
tus and the severity of subjective symptoms, as
outcomes for this study.
The standard mercury sphygmomanometer is the
most common device used to measure blood pressure
[2]. The accuracy of automatic blood pressure measure-
ment is still controversial [20,21]; therefore, the mercury
sphygmomanometer is considered to be the ‘gold stan-
dard’ for measuring blood pressure. To avoid the white-
coat effect [22], the CRC will not wear a white coat dur-
ing this clinical study.
This study will be the first randomized trial to investi-
gate the effectiveness of qigong exercises for the treat-
ment of pre- and mild hypertension. The main focus of
this trial is to investigate the role of qigong in reducing
the blood pressure of patients with pre- or mild hyper-
tension. This trial will contribute information needed to
begin answering important clinical questions regarding
the effects of qigong in lowering the blood pressure of
patients with pre- and mild hypertension. Although the
trial is not sufficiently powered to determine the effec-
tiveness of qigong on hypertension, we will compare the
effect size between groups in order to form larger-scale
trials in the future.
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